NCT02267642View on ClinicalTrials.gov

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions

Psoriatic Arthritis

Interventions

BIOLOGICAL

AbGn-168H

monoclonal antibody

Trial Locations (7)

34239

Sarasota Arthritis Research Center, Sarasota

48910

Justus J. Fiechtner, MD, PC, Lansing

60611

Northwestern University, Chicago

75231

Metroplex Clinical Research Center, LLC, Dallas

92037

UC San Diego, La Jolla

94304

Stanford University, Palo Alto

98122

Seattle Rheumatology Associates/Swedish Clinical Research, Seattle

All Listed Sponsors

lead

AbGenomics B.V Taiwan Branch

INDUSTRY

NCT02267642 - A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter